Chief Scientific Officer · Akero Therapeutics, Inc. (AKRO)

Timothy Rolph

FY2023 is the first fiscal year CompBrief holds for Timothy Rolph as a named executive officer of Akero Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$3,490,850

Salary $506,000Stock awards $645,715

3rd of 5 named executive officers at Akero Therapeutics by FY2023 total.

5 named officers on file for Akero Therapeutics, FY2023

Timothy Rolph’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • AKRO’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Akero Therapeutics’s whole pay program stands against its peers

  • Akero Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AKRO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Timothy Rolph’s full pay file as a PDF — free

More than this page: up to 10 years of Timothy’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Timothy Rolph compensation by year

Akero Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Akero Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$506,000
Bonus$0
Stock awards$645,715
Option awards$2,122,820
Non-equity incentive$216,315
Pension and deferred compensation$0
All other$0
Total$3,490,850

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Akero Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0000950170-24-049210, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Akero Therapeutics, Inc. filed document, accession 0000950170-24-049210. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU32,497$758,805—
RSU14,397$336,170—
Option43,611—$21.10
Option64,785—$42.95
Option146,237—$19.87
Option17,779—$28.35

Per the Outstanding Equity Awards at Fiscal Year-End table in Akero Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

105 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-12-09Disposition to the issuer derivative—2,328—0
2025-12-09Disposition to the issuer derivative—84,051—0
2025-12-09Disposition to the issuer derivative—3,421—0
2025-12-09Disposition to the issuer derivative—5,032—0
2025-12-09Disposition to the issuer derivative—119,969—0
2025-12-09Disposition to the issuer derivative—56,579—0
2025-12-09Disposition to the issuer—43,810—0
2025-12-09Disposition to the issuer derivative—26,152—0

The 8 most recent of 105 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Akero Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Andrew ChengPresident and Chief Executive Officer$8,834,907
William WhiteChief Financial Officer$4,292,266
Timothy Rolph · this pageChief Scientific Officer$3,490,850
Catriona YaleChief Development Officer$3,446,598
Jonathan YoungChief Operating Officer$3,440,888

The full Akero Therapeutics compensation record

free company brief

This page is one person within Akero Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Akero Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Akero Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Timothy Rolph's compensation dossier · One-time report. No refunds.